Revolution Medicines, Inc. (RVMD) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Revolution Medicines (RVMD) Q1 2026: $2.1B Capital Raise Fuels RAS Inhibitor Pipeline Acceleration
May 07, 2026
-
Revolution Medicines (RVMD) Q4 2025: R&D Spend Surges 57% as Eight Registrational Trials Drive Pipeline Expansion
February 26, 2026
-
Revolution Medicines (RVMD) Q3 2025: R&D Spend Surges 73% as Three RAS Inhibitors Advance Toward Global Launch
November 06, 2025
-
Revolution Medicines (RVMD) Q2 2025: $2B Royalty Pharma Deal Expands Global Oncology Ambition
August 06, 2025
-
Revolution Medicines (RVMD) Q1 2025: R&D Spend Jumps 74% as Phase III RAS Portfolio Expands
July 04, 2025
-
Revolution Medicines (RVMD) Q4 2024: R&D Spend Jumps 27% as Late-Stage RAS Pipeline Accelerates
February 26, 2025